Supplement to
The American Journal of Tropical Medicine and Hygiene
# Research for an Unexpected Epidemic: The EU Response against Ebola

Sponsored by The European Commission’s Directorate-General for Research and Innovation and the Institute of Tropical Medicine in Antwerp on behalf of the Ebola-Tx Consortium

Monday, October 26, 7:15 p.m. – 9 p.m.
Marriott – Grand Ballroom Salon H

This symposium aims to present the European research response to the Ebola outbreak, focusing on the challenges and opportunities it revealed for all research partners. The major funder of EU Ebola research, the European Commission, will present an overview of the various funding mechanisms mobilized for this outbreak including collaboration with the pharmaceutical industry, as well as the spectrum of research gaps addressed. Industry and academic researchers will then present the most important European research projects against Ebola, the multiple and diverse challenges they faced and how they managed to overcome them, as well as their results and implications for future research. The session will culminate in a discussion on the lessons learned from this outbreak. A paradigm on how established networks of cooperation among funders can facilitate a coordinated research response to an epidemic like Ebola will be presented.

**CHAIR**

Line Matthiessen  
European Commission’s Directorate-General for Research and Innovation, Brussels, Belgium  
Bruno Gryseels  
Institute of Tropical Medicine, Antwerp, Belgium

## The EU Research Response to the Ebola Crisis

Line Matthiessen  
European Commission’s Directorate-General for Research and Innovation, Brussels, Belgium

### Innovative Medicines Initiative: A Tool Also for Preparedness Research!

Angela Wittelsberger  
Innovative Medicine Initiative (IMI), Brussels, Belgium

### Joining Forces with Industry: Vaccine Development

Johan van Hoof  
Janssen Pharmaceuticals, Beerse, Belgium

### Questions on EC Research Funding Tools, IMI, Vaccine Trial

### Study Design Options for Therapeutic Trials — Ethics, Settings and Practicalities

Peter Horby  
Oxford University, Oxford, United Kingdom

---

<table>
<thead>
<tr>
<th>课题</th>
<th>负责人</th>
<th>机构</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trials of Convalescent Blood/Plasma</td>
<td>Johan van Griensven</td>
<td>Institute of Tropical Medicine, Antwerp, Belgium</td>
</tr>
<tr>
<td>The JIKI Trial</td>
<td>Denis Malvy</td>
<td>INSERM, Bordeaux, France</td>
</tr>
<tr>
<td>Questions on Clinical Trials</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cooperation between Funders Benefits Research</td>
<td>Penny Heaton</td>
<td>Bill &amp; Melinda Gates Foundation, Seattle, WA, United States</td>
</tr>
<tr>
<td>The Way Forward: GloPID-R</td>
<td>Marc Ouallette</td>
<td>Canadian Institutes of Health Research, Institute of Infection and Immunity, Quebec City, QC, Canada</td>
</tr>
<tr>
<td>Panel Discussion: Challenges and Lessons Learned</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>